Zaltrap (aflibercept)

How Much Does that Drug Cost? You Have to be Kidding!

How much money is a drug worth and how much money should we be willing to spend for it have been questions that have been increasingly asked by economists, doctors and cancer survivors. Last month in an Op-Ed article three doctors from Memorial Sloane Kettering Cancer Center in New York (Sloane) let the world know that Sloane had made a decision not to use a drug made by Sanofi to treat colon cancer. The FDA recently approved the drug, Zaltrap because it extended life by a median of 1.4 months, but at a cost of more than $100,000 per year. [...]

On the Horizon- Final Results of VENICE First-Line Hormone-Refractory Metastatic Prostate Cancer Trial Expected in 2012

Regeneron Pharmaceuticals, Inc. announced that the Phase 3 VENICE clinical trial evaluating the investigational agent Zaltrap (aflibercept) in the first-line treatment of men with castrate resistant prostate cancer will continue to completion as planned. They have not been asked to make any modifications due to efficacy or to safety concerns. This decision is based on the recommendation of an Independent Data Monitoring Committee (IDMC) following a planned interim analysis. According to George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Research Laboratories, . "We look forward to the final results of this trial next year [...]